KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Accumulated Expenses (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Accumulated Expenses data on record, last reported at $12.2 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 78.25% year-over-year to $12.2 million; the TTM value through Dec 2025 reached $12.2 million, down 78.25%, while the annual FY2025 figure was $12.2 million, 78.25% down from the prior year.
  • Accumulated Expenses reached $12.2 million in Q4 2025 per EBS's latest filing, down from $36.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $88.7 million in Q4 2021 and bottomed at $12.2 million in Q4 2025.
  • Average Accumulated Expenses over 5 years is $49.8 million, with a median of $55.6 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: crashed 78.69% in 2023, then surged 201.61% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $88.7 million in 2021, then decreased by 1.58% to $87.3 million in 2022, then plummeted by 78.69% to $18.6 million in 2023, then soared by 201.61% to $56.1 million in 2024, then crashed by 78.25% to $12.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $12.2 million in Q4 2025, $36.6 million in Q3 2025, and $31.5 million in Q2 2025.